AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06111573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium
Description: Diagnostic Criteria for Temporomandibular Disorders was used in the diagnosis of patients with myofascial pain. Control group using Diclofenac Sodium for myofascial pain treatment. Medical treatment with Diclofenac Sodium (Voltaren 75 mg, 2x1 ) + Occlusal Splint treatment was applied. Occlusal Splints were made of hard acrylic with a flat surface and were used only for 8 hours during sleep for 3 months. 500 mg Paracetamol tablet was prescribed to the patients as a rescue painkiller if they needed painkillers.
Study NCT05061888 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smart Intervention for Food Waste Management and Replacing current diet with Fruits and Vegetables
Description: Will receive a Smart Intervention on Food Waste Management and replacing less healthy foods with fruits and vegetables.
Study NCT05061888 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Smart Intervention for Stress Managment
Description: Will receive a Smart Intervention on stress management practices and strategies.
Study NCT05435248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10375
Description: HS-10375 will be administered orally once daily in a continuous regimen
Study NCT05344092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VetEd Mobile Application
Description: Participants be provided with the VetEd mobile app, with instructions on how to utilize the app at home over a four-week period
Study NCT04364672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-labeled DPA-714 PET scan
Description: One PET with \[18F\]DPA-714 before chemotherapy treatment begins. One more PET with \[18F\]DPA-714 within 4 weeks after completing NACT including at least 2 cycles administered; before surgery
Study NCT05331664 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars plana vitrectomy
Description: Standard of care surgery
Study NCT05331664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide 40mg/mL
Description: Sub-tenon injection of triamcinolone acetonide (40mg/mL) at the time of surgery
Study NCT05331664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin
Description: Antibiotic eye drop 4 times per day for 1 week after surgery
Study NCT06002022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REBECCA system (smartwatch + mobile app use)
Description: Patients will be trained in the use of the REBECCA system, which will provide in-depth information about their lifestyle (including physical activity levels, dietary habits, sleep quality and social mobility), as well as of their online behaviour (with outcome indicators of anxiety, PTSD and depression development) and self- or companion-reported measures of emotional state and quality of life. Based on the additional information, exploiting the enhanced monitoring capabilities of the REBECCA system, the supervising clinicians will be given the opportunity to continuously evaluate the progress of the patients, allowing them to schedule up to 3 phone-based consultation sessions in the first 12 months of treatment
Study NCT04941274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: An initial dose of 200 mg twice daily and at an MTD dose will be administered orally every day of each 28-day cycle.
Study NCT06414317 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Assessment of Distress
Description: Undergo psychological distress screening
Study NCT06414317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consultation Visit
Description: Attend consultations
Study NCT06414317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Assessment
Description: Undergo malnutrition screening
Study NCT06414317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06414317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Receive access to bladder cancer ENST
Study NCT06414317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Attend virtual support group meetings
Study NCT04701437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer mentor
Description: Peer mentors will contact participants within 72 hours of enrollment to discuss the early release period, gauge their readiness for HCV treatment, and identify ancillary needs. They will also accompany the participant to their first medical appointment with an HCV provider and any future appointments if requested by the participant. Peer mentors will offer participants social support throughout the 6 months they are enrolled in the study.
Study NCT04701437 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Passive referral to a HCV provider
Study NCT06469073 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus thoracic muscle plane block or Erector spinal plane block
Description: Transversus thoracic muscle plane block or Erector spinal plane block
Study NCT04876716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azole
Description: Dosing according to the SPC
Study NCT04876716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Description: 200mg loading dose on day 1 and 100mg QD thereafter
Study NCT05331664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone 1%
Description: Steroid eye drop 4 times per day tapered by one drop weekly for 4 weeks (4/3/2/1 taper) after surgery
Study NCT05331664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine 1%
Description: Eye drop daily for 1 week after surgery
Study NCT05811572 — intervention group
Intervention type: DEVICE
Intervention: measurement of pelvic floor muscle with perinometer
Description: Questions the person's perceptions about low back pain and related disability VAS questions the person's perceptions about low back pain severity
Study NCT04823533 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic-placebo supplement
Description: A probiotic formulation containing two well-documented probiotic strains. The finished product is a lyophilized powder packaged in single-dose sticks sachets Excipients used were as follows: xylitol, maltodextrin, plum flavor, and malic acid.
Study NCT04823533 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic-placebo supplement
Description: A probiotic formulation containing two well-documented probiotic strains. The finished product is a lyophilized powder packaged in single-dose sticks sachets Excipients used were as follows: xylitol, maltodextrin, plum flavor, and malic acid.
Study NCT06253728 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High fiber and protein meal
Description: In the intervention participants are assigned to eat high protein and fiber meal that differ in protein source or structure.
Study NCT06253728 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control meal is low fiber and low protein meal.
Study NCT06628349 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein Isolate 90%
Description: Commercially available animal based protein powders
Study NCT06421818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baitouweng Tang
Description: Baitouweng Decoction is composed of four herbs: Baitouweng, Rhizoma coptidis, Phellodendri huangbai and Qin Pi.
Study NCT06421818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baitouweng Tang
Description: Baitouweng Decoction is composed of four herbs: Baitouweng, Rhizoma coptidis, Phellodendri huangbai and Qin Pi.
Study NCT06421818 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The same volume and color as Baitouweng Decoction.
Study NCT06075771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa Levodopa
Description: Patients will receive between one and three tablets per day of 150 mg L-DOPA (administered with 37.5 mg carbidopa) to achieve doses ranging from 150 to 450 mg/day.
Study NCT06075771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive between one and three placebo tablets per day matching the Carbidopa Levodopa tablet.
Study NCT06628349 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy Protein Isolate (90% Protein)
Description: Commercially available plant based protein powders
Study NCT04967755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jing-Si-Herbal-Tea
Description: Eligible patients were randomized to receive routine treatment alone based on the Novel Coronavirus Interim Guidelines for Clinical Management of SARS-CoV-2 Infection (Eleventh edition 2021) (control group) or the combination of routine treatment and JSHT (1 drink thrice daily for 7 days) (JSHT group) at the discretion of the attending clinicians. Routine treatment generally consisted of the supportive treatment such as oxygen therapy, antiviral medications and symptomatic therapies. Adherence to the study medications, clinical outcomes, the use of concomitant medications and adverse events were recorded. The following data were collected at admission: demographics, body mass index, smoking history, comorbidities, CURB-65 Score for pneumonia. Hemogram, laboratory testing, chest X-ray, and nucleic acid assays of SARS-CoV-2 were evaluated at admission and after randomization and on 7th day.
Study NCT05626686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLINY catheter
Description: Subjects using a single use catheter for bladder management at inclusion. During the study period, subjects will use the reusable CLINY catheter for 28 test-days
Study NCT06497686 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: mesoscale nonlinear optical gigascope
Description: An nonlinear optical microscope with ultra-large field of view and ultra-high resolution.
Study NCT04797013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rt-PA
Description: Subjects will be randomized to rhTNK-tPA or rt-PA in a 1:1 ratio.
Study NCT04797013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhTNK-tPA
Description: Subjects will be randomized to rhTNK-tPA or rt-PA in a 1:1 ratio.
Study NCT05836961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Benazir Nashonuma Program (BNP)
Description: Dietary supplement for pregnant women and lactating mothers during the first six months of lactation:~Maamta is a 75-gram sachet made from peanut butter with 400 kcal of energy~Dietary supplement for children aged 6-23 months:~Wawamum is a lipid-based nutrient supplement consisting of skimmed milk powder, micronutrients, vegetable oil, roasted chickpeas and antioxidants. Wawamum covers the recommended daily dose of most micronutrients and 255 kcal of energy (1/4 of daily energy requirements for children in this age range)~Conditional Cash Transfers (CCT):~This includes stipends of PKR 2000 during pregnancy contingent on three antenatal care visits, consuming SNF, attending awareness sessions on health and nutrition, getting two doses of tetanus toxoid and institutional delivery. After delivery PKR 2000/- for boys and 2500/- for girls are paid as incentives conditioned on getting child's birth registered, routine immunization and consumption of SNF by the child from 6-23 months
Study NCT06228183 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: comprehensive rehabilitation therapy
Description: Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
Study NCT06228183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive rehabilitation therapy
Description: Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
Study NCT06228183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
Study NCT06228183 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube Feeding
Description: Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
Study NCT04805931 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral economics
Description: Tailored behavioral economic text messaging vs. standard text messaging
Study NCT06628349 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Organic Pea Protein Isolate
Description: Commercially available plant based protein powders
Study NCT06628349 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo (Water)
Description: Normal drinking water
Study NCT06235242 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GT201 injection in combination with teraplizumab injection
Description: GT201 injection in combination with teraplizumab injection for treatment of patients with non-small cell lung cancer
Study NCT05718076 — intervention group
Intervention type: PROCEDURE
Intervention: cataract surgery
Description: Phacoemulsification combined trifocal lens implantation
Study NCT04914130 — intervention group
Intervention type: OTHER
Intervention: Study specific testing procedures
Description: Study specific procedures includes blood sampling, neurocognitive testing, respiratory questionnaire, brain MRI for MRI substudy group, lumbar puncture for MRI substudy group, etc
Study NCT06497647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulbutiamine
Description: sulbutiamine will be used by oral route 100 mg daily for 1 month and follow up will be done every 1 month till 3 months.~it will be used alone in group B and combined with imipramine in group C
Study NCT06500182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hippotherapy sessions
Description: Patients benefit from the hippotherapy sessions in additional to continuing to receive traditional care.
Study NCT06782035 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ora-Aid-Oral Wound Dressing
Description: Intended as a physical barrier for temporary protection of oral mucosal tissue and to provide pain relief. This product is a non-eugenol protective material applied to intraoral wounds. Ora-Aid is a new concept of pasting intra-oral patch to protect the affected area such as post implant, extraction, orthodontic, and ulcers. This new concept of pasting intra-oral wound dressing is designed to protect the affected area and aid natural healing.
Study NCT06782035 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich fibrin
Description: It has been reported that the use of Platelet-Rich Fibrin (PRF) to cover palatal wounds accelerates healing and reduces postoperative morbidity. Studies have demonstrated that PRF supports key processes in wound healing, such as immunity, angiogenesis, and cellular proliferation. Its use has garnered significant interest, particularly in non-healing wounds and areas left to heal by secondary intention after surgery. Leukocyte and Platelet-Rich Fibrin (L-PRF) is frequently used in periodontal surgical applications. The platelets and growth factors it contains accelerate the healing process and facilitate tissue repair.
Study NCT06782035 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Palatal Stent
Description: Palatal stents help prevent complications such as infection or excessive discomfort. These plates are typically customized to fit the patient's palate by taking impressions before the surgery. Once placed, they serve as a barrier, especially during the early stages of healing. Additionally, they may reduce the need for postoperative interventions, such as the use of strong painkillers.
Study NCT06497686 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fluorescence microscope
Description: An optical microscope used to examine the fluorescence signal from stained tissues.
Study NCT06497647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipramine
Description: imipramine will be used by oral route 25 mg daily for 1 month and follow up will be done every 1 month till 3 months.~it will be used alone in group A and combined with sulbutiamine in group C
Study NCT06494904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: All patients will receive 3 pills and will be observed for 2 hours post-study medication administration with repeated COWS at approximately hours 1 and 2. All participants will be given a referral for ongoing MOUD and will be discharged with a prescription for 16 mg daily of buprenorphine daily.
Study NCT06494904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: All patients will receive 3 pills and will be observed for 2 hours post-study medication administration with repeated COWS at approximately hours 1 and 2. All participants will be given a referral for ongoing MOUD and will be discharged with a prescription for 16 mg daily of buprenorphine daily.
Study NCT05154214 — intervention group
Intervention type: PROCEDURE
Intervention: Adenotonsillectomy
Description: Removal of tonsils and adenoids
Study NCT05836259 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: TN-201
Description: TN-201 is a recombinant adeno-associated virus serotype 9 (AAV9) containing Myosin Binding Protein C (MYBPC3) transgene. It is a single (one-time) intravenous dose.
Study NCT05895045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Restorative Vinyasa Yoga
Study NCT06603831 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: patients treated using 3D technology and Patient-Specific Instrumentation
Description: 3D Digital surgery includes:~* 3D Surgical Planning using biomedical engineering software; 3D visualization of the patients anatomy and surgical simulation.~* Use of personalized surgical guides created through additive manufacturing.~* Use of personalized implants created through additive manufacturing.~  3 surgical procedures are studied in this study; radius osteotomy, acetabular arthroplasty and spinal arthrodesis
Study NCT06603831 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients treated with conventional surgery, without using 3D technology
Description: Conventional surgery includes:~* 2D planning using TC and x-rays~* Free-hand surgery~* Use of generic, non-personalized implants~  3 surgical procedures are studied in this study; radius osteotomy, acetabular arthroplasty and spinal arthrodesis
Study NCT04984590 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: IOPCL AMD MAG
Description: The IOPCL MAG (intraocular pseudophakic capsular lens magnifier) consists of a 4.5 mm diameter optic. The central 1.8mm of the anterior surface has a power of 10.0 diopters. This IOPCL MAG will be implanted over an Alcon Model SN60WF or SA60AT intraocular lens to improve near vision.
Study NCT06596772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB04 (proposed biosimilar to etanercept)
Description: MB04 50 mg/week via subcutaneous injection